Assessment of Non-Cardiac Congenital Malformations and in Utero Exposure to Modafinil/Armodafinil in the Sentinel Distributed Database Read more about Assessment of Non-Cardiac Congenital Malformations and in Utero Exposure to Modafinil/Armodafinil in the Sentinel Distributed Database
Prevalence of Selected Health Conditions among Individuals with Childbearing Potential to Inform the Development of the Pregnancy Safety Study Framework Read more about Prevalence of Selected Health Conditions among Individuals with Childbearing Potential to Inform the Development of the Pregnancy Safety Study Framework
Assessing Exposure to Recently Approved Medications to Inform Feasibility for Signal Identification Analyses in the FDA’s Sentinel System Read more about Assessing Exposure to Recently Approved Medications to Inform Feasibility for Signal Identification Analyses in the FDA’s Sentinel System
Characterizing Infants in the Sentinel Distributed Database Mother-Infant Linkage Table Read more about Characterizing Infants in the Sentinel Distributed Database Mother-Infant Linkage Table
Characterizing Inpatient Electronic Health Records (EHR) from a Large Hospital Network for Use in Neonatal Pharmacoepidemiology Studies in the United States Read more about Characterizing Inpatient Electronic Health Records (EHR) from a Large Hospital Network for Use in Neonatal Pharmacoepidemiology Studies in the United States
COVID-19 Related Changes in Healthcare Utilization Among Insured Persons in the U.S. and its Impact on Pharmacoepidemiologic Research Read more about COVID-19 Related Changes in Healthcare Utilization Among Insured Persons in the U.S. and its Impact on Pharmacoepidemiologic Research
Triple Challenges – Small Sample Size in Both Exposure and Control Groups to Scan Rare Maternal Outcomes in a Signal Identification Approach: A Simulation Study Read more about Triple Challenges – Small Sample Size in Both Exposure and Control Groups to Scan Rare Maternal Outcomes in a Signal Identification Approach: A Simulation Study
Duration of Follow Up for New Molecular Entities Approved in 2017: Third Descriptive Analysis Read more about Duration of Follow Up for New Molecular Entities Approved in 2017: Third Descriptive Analysis
Overview of CDER’s Real-World Evidence Demonstration Projects Read more about Overview of CDER’s Real-World Evidence Demonstration Projects
Tree-Based Mining of Real-World Data for Potential Safety Signals Associated with the Use of Dupilumab in the United States (2017-2023) Read more about Tree-Based Mining of Real-World Data for Potential Safety Signals Associated with the Use of Dupilumab in the United States (2017-2023)